THE "GOOGLE MAP" OF MOLECULES,

PREDICTIVE POWER AT YOUR FINGERTIPS

GDBspace / a SPACE PHARMACEUTICALS company

News

Space Pharmaceuticals completes Series A financing to advance AI-driven drug discovery

Space Pharmaceuticals, an AI-driven chemical space drug discovery company based in Basel, Switzerland, announced the completion of a Series A financing round of CHF 12 million, led by Venture Capital firm Cowin Capital.

Spinned-off from 20 years of computational chemistry research from Prof. Jean-Louis Reymond, University of Bern, Switzerland, Space Pharmaceuticals’ GDBspace drug discovery engine has a unique approach to the design of the largest and most diverse small molecule (incl. peptides and peptidomimetics) library till date, mapped with molecular fingerprints to decode this chemical space. A portfolio of Artificial Intelligence (AI)-augmented technologies and state-of-the-art algorithms, empower the evaluation of billions of molecules to design drugs faster and cheaper. The Space Peptides laboratory arm is specialised in peptide manufacturing, as well as in vitro / in vivo validation of the molecules of interests.

Dr. Runze He, CEO of Space Pharmaceuticals says: “The confidence of our investors together with successful partnerships with established pharma and biotech companies further validates our AI-driven discovery platform to de-risk drug discovery programs, increase success rates, and significantly reducing time and costs. With some of the first AI-designed drugs entering the clinic, we are convinced of the value of AI in de-risking and transforming the pharmacoeconomics of drug discovery.”

About Space Pharmaceuticals

Space Pharmaceuticals AG (“Space Pharmaceuticals”) is an AI-based drug discovery and peptide manufacture company. Its proprietary GDBspace discovery engine applies chemical space-based drug discovery, combined with artificial intelligence, to identify small molecules (incl. peptides and peptidomimetics) of interests in a precise and time-efficient manner –
hence de-risking projects, increasing success rates, and significantly reducing time and costs. The Space Peptides laboratory arm is specialized in peptide manufacturing, as well as in vitro / in vivo validation of the molecules of interests. For more information, please visit Space Pharmaceutical’s website at www.gdbspace.com, www.spacepeptides.com

Space Pharmaceuticals appoints Dr. Simon Nebel as Business advisor

Space Pharmaceuticals is pleased to welcome Dr. Simon Nebel as Business Advisor.

Dr. Simon Nebel has participated in the financing of a number of life science companies and the M&A transactions for Aravis portfolio companies. He has been the board member or observer in fourteen companies. Before joining Aravis, he was a group strategist at UBS. Dr. Nebel got his PhD in Biophysics at the Biocentre of the University of Basel and an MBA from the London Business School.

Space Pharmaceuticals appoints Prof. Hans-Joachim Böhm as Scientific advisor

Space Pharmaceuticals is pleased to welcome Prof. Hans-Joachim Böhm as Scientific advisor.

Prof. Hans-Joachim Böhm is a professor of Bioinformatics at the University of Basel, working on the development of new methods for computer-aided drug design, as well as a member of the Swiss Science Council. He worked for several years at Roche in both Basel and Palo Alto (USA) where he became global head of chemical research. He also worked at Siemens in Munich in the field of microelectronics research and then at BASF in Ludwigshafen in structure-based design of drugs. Prof. Böhm studied chemistry at the University of Karlsruhe where he did both his PhD and his Post Doc.

GDBspace, a Space Pharmaceuticals company, announces exclusive collaboration and licensing agreement with Sinqi Pharmaceutical to discover and develop novel ophthalmology therapies

GDBspace, a Space Pharmaceuticals company, specialized in chemical space based drug discovery, and Sinqi Pharmaceutical, a leading ophthalmology pharmaceutical company, announced today an exclusive global collaboration and licensing agreement to research, develop, manufacture and commercialize novel peptide drugs of an undisclosed ophthalmology target.

“Space Pharmaceuticals is rooted in a long history of computational chemistry research and has deep expertise of AI-based drug discovery. We believe this is a strong strategic opportunity to enhance our growing discovery portfolio”, said a spokesperson at Sinqi Pharmaceutical.

“This agreement with Sinqi Pharmaceutical further validates our expertise in AI discovery and preclinical development of peptide therapeutics”, said Dr. Runze He, CEO of Space Pharmaceuticals.

Under the terms of the agreement, Space Pharmaceuticals will be eligible to receive an undisclosed upfront cash payment as well as additional milestone payments based on development, regulatory and commercial milestones. In addition, Sinqi Pharmaceutical will pay royalties on future net sales on any product that may result from this collaboration. Financials of the agreement were undisclosed.

About Space Pharmaceuticals

Space Pharmaceuticals AG (“Space Pharmaceuticals”) is an AI-based drug discovery and peptide manufacture company. Its proprietary GDBspace discovery engine applies chemical space-based drug discovery, combined with artificial intelligence, to identify small molecules (incl. peptides and peptidomimetics) of interests in a precise and time-efficient manner –
hence de-risking projects, increasing success rates, and significantly reducing time and costs. The Space Peptides laboratory arm is specialized in peptide manufacturing, as well as in vitro / in vivo validation of the molecules of interests. For more information, please visit Space Pharmaceutical’s website at www.gdbspace.com, www.spacepeptides.com

About Sinqi Pharmaceutical

Shenyang Xingqi Pharmaceutical Co. Ltd. (“Sinqi Pharmaceutical”) (SZSE: 300573) is a leading, commercially successful, China-based pharmaceutical company principally engaged in the research, development, manufacture and distribution of ophthalmologic drugs. The company’s main products are ophthalmologic prescription drugs, including corneal repairing drugs, anti-infective drugs, anti-inflammatory drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. For more information, please visit Sinqi Pharmaceutical’s website at www.sinqi.com

Events

2. May 2022 - 3. May 2022
7. Apr 2022 - 8. Apr 2022